

IPV leads Iom Bioworks' Rs 4 Cr funding to revolutionise healthcare through gut microbiome science

12 June 2025 | News

Funds will be used to boost customer outreach, secure IP rights



Bengaluru-based startup Iom Bioworks, a deep science company pioneering microbiome-focused healthcare, has secured Seed Round funding in their Rs 4 crore Seed Round led by Inflection Point Ventures (IPV).

The capital will be leveraged for marketing, secure intellectual property claims, strengthen core infrastructure and scale scientific and commercial teams.

Founded in 2022, Iom Bioworks personalises health by identifying key bacteria in the gut and modulating them in a targeted manner for enhanced, improved overall health and well-being. Their patented platform combines large-scale knowledge graphed mined through Artificial Intelligence (AI) and advanced modelling techniques that ensures Iom achieves precise and personalised recommendations for its users.

Iom Bioworks reached more than 500 customers in just the first year and have 2 patents granted and 2 in advanced stages. They have key scientific publications in leading scientific journals. Iom Bioworks have Pan India logistics and have established digital access established for personalised microbiome services.

"Lifestyle diseases have been on the rise due to multiple reasons like poor diet, stress, lack of sleep and are intimately linked

to poor gut health and microbial composition. The gut microbiome plays a huge role in your digestion, immunity, metabolism, and even mood. Understanding it can help prevent a myriad of these diseases and also provide a better quality of life. Iom Bioworks is making this cutting-edge science accessible, personalised and importantly, actionable. With their vision and science, they make a compelling bet in preventive and therapeutic healthcare", says Vinay Bansal, Founder, IPV.

At a compound annual growth rate (CAGR) of 28%, the worldwide market for health tests, subscriptions, and wellness platforms is expected to reach \$900 billion by 2030. Iom Bioworks is well positioned to lead this transformation to personalised accessible gut health with its scalable approach, user focus and the foundation of deep science and research.

Image caption- L-R, Samik Ghosh, Co-Founder & Chief of Science & Technology; Dr Hiroaki Kitano, Co-Founder & Chief of Research & Collaboration; Bipin Pradeep Kumar, Co-Founder and CEO, Iom Bioworks